Search

everythinglearnresearchcommunity

for

Search:↓

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

RU58841 slowed hair loss for a DUPA sufferer after other treatments like finasteride, dutasteride, and minoxidil failed. Some users reported side effects with RU58841, while others did not experience any.

The user is exploring alternatives to hair transplants due to a weak donor area and is currently using finasteride, minoxidil, dermapen, low-level laser therapy, Nizoral shampoo, and a high-protein diet. They plan to switch to dutasteride and consider adding RU58841, while rejecting hair systems and considering a buzz cut.

The conversation discusses that dutasteride may be more effective than finasteride for frontal hair loss due to higher 5ar Type 1 enzyme activity in that area. Some users question the validity of this information, while others confirm it with additional sources.

A 47-year-old has been using finasteride since December 2022 to treat hair thinning and has seen gradual improvement, especially between March and August. They take 1mg three times a week and have noticed increased hair density and thickness.

The conversation discusses the anticipation for updates on GT20029, a potential hair loss treatment. Users also mention using Minoxidil, finasteride, and RU58841.

Treatments for hair loss, including Minoxidil, finasteride, and RU58841. The post discusses the potential benefits of Pyrilutamide compared to RU58841 in terms of strength and longevity.

Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.

The conversation discusses buying RU58841 directly from a Chinese supplier for cost savings. It mentions that companies like Anageninc and Actifolic do the same.

Genetic differences in hair follicles affect hair loss patterns. Treatments discussed include finasteride, dutasteride, minoxidil, and RU58841.

The conversation is about using adenosine, finasteride, and minoxidil for hair loss treatment. The user ordered a 0.75% adenosine solution and is currently using finasteride 1mg and minoxidil 5%.

The conversation discusses the potential availability of a new hair loss treatment, GT20029, on the grey market, with users suggesting it could be within a year but advising against using grey market products due to safety concerns and complexity of the drug.

Hair cloning and new treatments like ET-02, Veradermics (vdphl01), and wound-induced hair neogenesis show promise but are not yet widely available. Current effective treatments include minoxidil, finasteride, and dutasteride, with early intervention being crucial for better outcomes.

GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.

The conversation is about the availability of the research chemical GT20029 for hair loss treatment and when companies like Anageninc will have it. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

A 21-year-old with diffuse thinning hair is considering RU58841 due to side effects from topical finasteride and is asking for the lowest effective dose and time to see results from RU58841 users.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

The conversation discusses whether M44 had a hair transplant or uses finasteride, minoxidil, and dutasteride. Opinions vary, with some suggesting a transplant and others noting no clear signs of hair loss.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

Research and science related to a minor improvement in hair growth caused by the use of verteporfin, as well as potential treatments such as Minoxidil, Finasteride, and RU58841.

A 26-year-old individual treating hair loss since 19, using a regimen of Finasteride, Cyproterone, Oral Minoxidil, Microneedling, Dutasteride, and newly added RU58841. They're seeking advice from other RU58841 users about their experiences.

A 19-year-old is experiencing hair thinning and recession above the temples, causing stress and consideration of starting finasteride despite financial constraints. They are unsure whether to begin treatment immediately or wait to assess the situation further.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly credits a person for the potential success of a treatment called GT20029.

Mixing RU58841 with minoxidil compounded with tretinoin is discussed, with concerns about systemic absorption. Topical dutasteride and finasteride are also mentioned as treatments, with varying personal experiences and concerns about side effects.

A 19-year-old is experiencing hair thinning and considering using RU58841 alongside minoxidil, which initially worked but lost effectiveness. Others advise caution, suggesting safer alternatives like topical finasteride and consulting a doctor before using unapproved treatments like RU58841.

The conversation discusses the anticipated release of GT20029, with some users expressing skepticism about its availability. It also mentions the use of treatments like Minoxidil, finasteride, RU58841, and dutasteride for hair loss.

The conversation is about hair loss treatments, specifically discussing RU58841, with concerns about its safety and lack of research. Alternatives like finasteride, dutasteride, and minoxidil are mentioned, with some users sharing personal experiences and side effects.

RU58841 is not FDA approved, and users are discussing its availability and legitimacy in India, with some mentioning brands like Vantanex and Capomil. One user warns about the risk of gyno from RU58841, advising to stop use at the first sign of sensitivity.